 | Up a level |
Journal Article
Kim, Dong-Wan, Tan, Daniel Shao-Weng, Aix, Santiago Ponce, Sequist, Lecia V., Smit, Egbert F., Hida, Toyoaki, Yang, James Chih-Hsin, Felip, Enriqueta, Seto, Takashi, Grohe, Christian, Wolf, Juergen, Ko, Jinnie, Diallo, Mariama, Pultar, Philippe, Giovannini, Monica and Kim, Sang-We (2018). Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Tan, Daniel S-W, Leighl, Natasha B., Riely, Gregory J., Yang, James C-H, Sequist, Lecia, V, Wolf, Juergen, Seto, Takashi, Felip, Enriqueta, Aix, Santiago P., Jonnaert, Maud, Pan, Chun, Tan, Eugene Y., Ko, Jinnie, Moody, Susan E. and Kim, Dong-Wan (2020). Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Resp. Med., 8 (6). S. 561 - 573. OXFORD: ELSEVIER SCI LTD. ISSN 2213-2600